Taxotere, Docetaxel Newswire (Page 2)

Comprehensive Real-Time News Feed for Taxotere, Docetaxel (generic). (Page 2)

Results 21 - 40 of 506 in Taxotere, Docetaxel (generic)

  1. Dose-dense sequential adjuvant chemotherapy followed, as indicated,...Read the original story

    Tuesday Jul 15 | BioMed Central

    George Fountzilas , Urania Dafni , Christos Papadimitriou , Eleni Timotheadou , Helen Gogas , Anastasia G Eleftheraki , Ioannis Xanthakis , Christos Christodoulou , Angelos Koutras , Christos N Papandreou , Pavlos Papakostas , Spyros Miliaras , Christos Markopoulos , Constantine Dimitrakakis , Panagiotis Korantzopoulos , Charisios Karanikiotis , ... (more)

    Comment?

  2. Peregrine Pharmaceuticals' (PPHM) CEO Steven King on Q4 2014 Results - Earnings Call TranscriptRead the original story

    Monday Jul 14 | Seeking Alpha

    Good day, ladies and gentlemen, and welcome to the Peregrine Pharmaceuticals, Incorporated Fourth Quarter and Full Fiscal Year 2014 Financial Results Conference Call.

    Comment?

  3. Comparison of molecular and immunocytochemical methods for detection...Read the original story

    Monday Jul 14 | BioMed Central

    Disseminated tumor cells have potential to predict the effect of adjuvant treatment.

    Comment?

  4. Peregrine Pharmaceuticals Inc - 10-K - Management's Discussion And...Read the original story

    Monday Jul 14 | Hispanic Business

    The following discussion is included to describe our financial position and results of operations for each of the three years in the period ended .

    Comment?

  5. Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal...Read the original story

    Monday Jul 14 | Freshnews

    "Our overall strategy is focused on advancing the bavituximab clinical program, engaging with potential partners, clinicians and researchers that can help expand potential indications and combinations for bavituximab while we continue to prepare for commercial activities and work toward maintaining the revenue growth seen for our wholly-owned ... (more)

    Comment?

  6. Fast TrackRead the original story w/Photo

    Oct 18, 2013 | WTVF Nashville

    Speeding the development and availability of drugs that treat serious diseases are in everyone's interest, especially when the drugs are the first available treatment.

    Comment?

  7. Astellas Pharma Inc. Details Pipeline Progress At R&D MeetingRead the original story

    Friday Jul 11 | BioSpace

    TOKYO, July 11, 2014 /PRNewswire/ -- Astellas announced progress on the Company's efforts to reshape its research framework at its R&D meeting held in Tokyo on the 10th July.

    Comment?

  8. Medivation, Inc. Announces Change In Executive Management TeamRead the original story

    Friday Jul 11 | BioSpace

    Medivation, Inc. today announced Dawn Svoronos has been appointed as its chief commercial officer, reporting to David Hung, M.D., founder, chief executive officer and president of Medivation.

    Comment?

  9. Medivation Announces Change in Executive Management TeamRead the original story

    Thursday Jul 10 | Freshnews

    Ms. Svoronos currently is a member of Medivation's Board of Directors and is a former president of Europe and Canada for Merck & Co.

    Comment?

  10. Medivation Set To Go Higher As Prostate Cancer Drug Xtandi Quickly Approaches Blockbuster StatusRead the original story w/Photo

    Thursday Jul 10 | Seeking Alpha

    When scouring biotechnology stocks to invest in, I look for undervalued companies that are developing or have approved drugs to treat diseases with high unmet clinical need with the potential to reach blockbuster status .

    Comment?

  11. Cheap drug boosts prostate cancer survivalRead the original story

    Sunday Jul 6 | The Daily Record

    A cheap, decades-old chemotherapy drug extended life by more than a year when added to standard hormone therapy for men whose prostate cancer has widely spread, doctors reported Sunday.

    Comment?

  12. Cortice Announces Enrollment of a Phase 1 Clinical Trial Evaluating...Read the original story

    Monday Jul 7 | GlobeNewswire

    Cortice Biosciences announced today that enrollment has begun in a Phase 1 trial designed to evaluate safety, tolerability and preliminary efficacy of the company's lead drug candidate, TPI 287, for treatment of patients with progressive supranuclear palsy and corticobasal degeneration .

    Comment?

  13. Fast TrackRead the original story w/Photo

    Oct 18, 2013 | WTVF Nashville

    Speeding the development and availability of drugs that treat serious diseases are in everyone's interest, especially when the drugs are the first available treatment.

    Comment?

  14. [Research Article] Exosomes from bone marrow mesenchymal stem cells...Read the original story

    Saturday Jul 5 | Science

    Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards.

    Comment?

  15. BIND Therapeutics Ends Cancer Drug Pact With Amgen; Stock Down -12.19% At 10:02AM ET On ThursdayRead the original story

    Thursday Jul 3 | BioSpace

    BIND Therapeutics Announces Completion Of Collaboration Agreement With Amgen CAMBRIDGE, Mass., Jul 02, 2014 -- BIND Therapeutics, Inc. BIND -9.78% , a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today the completion of its collaborative research program with Amgen Inc.

    Comment?

  16. Can the Japanese car factorymethods that transformed aSeattle hospital work on the NHS?Read the original story

    Thursday Jul 3 | Lucianne.com

    Can the Japanese car factory methods that transformed a Seattle hospital work on the NHS? Telegraph [UK], by Nick Allen One day recently, Andrea Sangrey, an oncology pharmacist, mixed up two chemotherapy drugs while preparing a prescription.

    Comment?

  17. Study Findings from Yanbian University Broaden Understanding of...Read the original story

    Wednesday Jul 2 | Hispanic Business

    However, the anti-metastatic efficacy of small-sized nanocarriers loaded with taxanes such as docetaxel has not yet been investigated in malignant breast cancer."

    Comment?

  18. BIND Therapeutics Announces Completion of Collaboration Agreement with AmgenRead the original story

    Wednesday Jul 2 | Freshnews

    BIND Therapeutics, Inc. , a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today the completion of its collaborative research program with Amgen Inc. originally entered into in January 2013.

    Comment?

  19. Ethanol diluent in injectables an intoxication risk says Us FdaRead the original story w/Photo

    Jun 24, 2014 | In-PharmaTechnologist.com

    The use of ethanol as a diluent in injectables is under the spotlight following a new US FDA warning that its presence in the cancer medicine docetaxel poses an intoxication risk.

    Comment?

  20. Can Cancer Patients Really Get 'Drunk' From Docetaxel?Read the original story w/Photo

    Jun 23, 2014 | Forbes.com

    The FDA issued an alert last Friday that some patients have reported feeling intoxicated after receiving their infusions of the chemotherapeutic drug, docetaxel.

    Comment?